Skip to main content


Risk Factors for CD4 Lymphopenia in Patients Treated With a Tenofovir/Didanosine High Dose-containing Highly Active Antiretroviral Therapy Regimen

Article metrics

  • 728 Accesses

In this study, the dynamics of CD4 cell depletion during tenofovir/didanosine co-administration were analysed. Ninety-five HIV-positive patients were followed for 562 days, and 37 lost at least 50 CD4 cells, with a median delay of 274 days. Cox analysis showed that the CD4 cell decrease was associated with a duration of treatment by didanosine of more than 853 days and a didanosine dose of more than 5.50 mg/kg.

Author information

Correspondence to Viviane Loungoussou.

Rights and permissions

Reprints and Permissions

About this article


  • Infectious Disease
  • Cancer Research
  • Didanosine
  • Lymphopenia
  • Cell Depletion